1. Home
  2. LIDR vs CGTX Comparison

LIDR vs CGTX Comparison

Compare LIDR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AEye Inc.

LIDR

AEye Inc.

HOLD

Current Price

$2.19

Market Cap

118.0M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.48

Market Cap

132.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIDR
CGTX
Founded
2013
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.0M
132.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LIDR
CGTX
Price
$2.19
$1.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$3.33
AVG Volume (30 Days)
1.4M
923.1K
Earning Date
02-19-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$182,000.00
N/A
Revenue This Year
$2.76
N/A
Revenue Next Year
$2,830.58
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$0.22
52 Week High
$6.44
$3.83

Technical Indicators

Market Signals
Indicator
LIDR
CGTX
Relative Strength Index (RSI) 47.60 47.64
Support Level $2.09 $1.34
Resistance Level $2.32 $1.62
Average True Range (ATR) 0.13 0.11
MACD 0.00 -0.00
Stochastic Oscillator 61.61 48.28

Price Performance

Historical Comparison
LIDR
CGTX

About LIDR AEye Inc.

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: